Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

How far will the Voyager® take us?

Levin VA.

CNS Oncol. 2019 Mar;8(1):CNS26. doi: 10.2217/cns-2018-0019. Epub 2019 Feb 15. No abstract available.

2.

Drug discovery in neuro-oncology: challenges in the path forward.

Levin VA.

Neuro Oncol. 2018 Mar 27;20(4):435-436. doi: 10.1093/neuonc/noy004. No abstract available.

3.

Estrogen therapy for osteoporosis in the modern era.

Levin VA, Jiang X, Kagan R.

Osteoporos Int. 2018 May;29(5):1049-1055. doi: 10.1007/s00198-018-4414-z. Epub 2018 Mar 8. Review.

PMID:
29520604
4.

Understanding brain penetrance of anticancer drugs.

Levin VA, Ellingson BM.

Neuro Oncol. 2018 Apr 9;20(5):589-596. doi: 10.1093/neuonc/noy018.

5.

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

Levin VA, Ictech SE, Hess KR.

CNS Oncol. 2018 Apr;7(2):CNS16. doi: 10.2217/cns-2017-0031. Epub 2018 Jan 30. Review.

6.

Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization.

Vartanyan EV, Tsaturova KA, Devyatova EA, Mikhaylyukova AS, Levin VA, Petuhova NL, Markin AV, Steptsova EM.

Gynecol Endocrinol. 2017;33(sup1):8-11. doi: 10.1080/09513590.2017.1399699.

PMID:
29264980
7.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

8.

CNS Anticancer Drug Discovery and Development: 2016 conference insights.

Levin VA, Abrey LE, Heffron TP, Tonge PJ, Dar AC, Weiss WA, Gallo JM.

CNS Oncol. 2017 Jul 18. doi: 10.2217/cns-2017-0014. [Epub ahead of print]

9.

Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.

Levin VA, Chan J, Datta M, Yee JL, Jain RK.

J Neurooncol. 2017 Sep;134(2):325-330. doi: 10.1007/s11060-017-2528-3. Epub 2017 Jun 19.

PMID:
28631191
10.

Comparative analysis of different variants of the Uzawa algorithm in problems of the theory of elasticity for incompressible materials.

Styopin NE, Vershinin AV, Zingerman KM, Levin VA.

J Adv Res. 2016 Sep;7(5):703-7. doi: 10.1016/j.jare.2016.08.001. Epub 2016 Aug 8.

11.

Personalized medicine in neuro-oncology.

Levin VA.

CNS Oncol. 2016;5(2):55-8. doi: 10.2217/cns-2016-0006. Epub 2016 Mar 21. No abstract available.

12.

CNS Anticancer Drug Discovery and Development Conference White Paper.

Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC.

Neuro Oncol. 2015 Nov;17 Suppl 6:vi1-26. doi: 10.1093/neuonc/nov169.

13.

Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.

Levin VA.

Oncology (Williston Park). 2015 Apr;29(4):264, 266-8. No abstract available.

14.

Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.

Levin VA, Mendelssohn ND, Chan J, Stovall MC, Peak SJ, Yee JL, Hui RL, Chen DM.

J Neurooncol. 2015 Mar;122(1):145-50. doi: 10.1007/s11060-014-1693-x. Epub 2015 Jan 11.

PMID:
25575937
15.

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative.

Neuro Oncol. 2015 Feb;17(2):266-73. doi: 10.1093/neuonc/nou155. Epub 2014 Sep 19.

16.

Getting more out of survival data by using the hazard function.

Hess KR, Levin VA.

Clin Cancer Res. 2014 Mar 15;20(6):1404-9. doi: 10.1158/1078-0432.CCR-13-2125. Epub 2014 Feb 5.

17.

Treatment of anaplastic oligodendrogliomas: should resources be used to codify the old or to create the new?

Levin VA.

Oncology (Williston Park). 2013 Apr;27(4):322, 324. No abstract available.

18.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY.

Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.

19.

Ask the Experts: How best to treat recurrent glioma.

Levin VA.

CNS Oncol. 2012 Sep;1(1):21-4. doi: 10.2217/cns.12.3. No abstract available.

20.

Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.

Levin VA, Panchabhai S, Shen L, Baggerly KA.

Proteome Sci. 2012 Jan 25;10(1):5. doi: 10.1186/1477-5956-10-5.

21.

Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.

Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK.

Cancer. 2012 Jul 15;118(14):3599-606. doi: 10.1002/cncr.26663. Epub 2011 Nov 15.

22.

A systematic approach to the management of patients with brain metastases of known or unknown primary site.

Kyritsis AP, Markoula S, Levin VA.

Cancer Chemother Pharmacol. 2012 Jan;69(1):1-13. doi: 10.1007/s00280-011-1775-9. Epub 2011 Nov 1. Review.

PMID:
22042515
23.

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.

Kyritsis AP, Levin VA.

Cancer Chemother Pharmacol. 2011 May;67(5):971-83. doi: 10.1007/s00280-011-1617-9. Epub 2011 Mar 27. Review.

PMID:
21442438
24.

Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents.

Kyritsis AP, Bondy ML, Levin VA.

Nutr Cancer. 2011;63(2):174-84. doi: 10.1080/01635581.2011.523807. Review.

25.

Role of bevacizumab therapy in the management of glioblastoma.

Peak SJ, Levin VA.

Cancer Manag Res. 2010 Apr 22;2:97-104.

26.

Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA.

J Neurooncol. 2011 Apr;102(2):273-80. doi: 10.1007/s11060-010-0313-7. Epub 2010 Jul 23.

27.

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95. doi: 10.1016/j.ijrobp.2009.12.061. Erratum in: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):6. Grewal, Jai [added].

28.

Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines.

Levin VA, Panchabhai SC, Shen L, Kornblau SM, Qiu Y, Baggerly KA.

J Proteome Res. 2010 Jan;9(1):179-91. doi: 10.1021/pr900392b.

29.

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK.

Br J Cancer. 2009 Aug 18;101(4):615-20. doi: 10.1038/sj.bjc.6605189.

30.

Displacive phase transitions at large strains: phase-field theory and simulations.

Levitas VI, Levin VA, Zingerman KM, Freiman EI.

Phys Rev Lett. 2009 Jul 10;103(2):025702. Epub 2009 Jul 8.

PMID:
19659221
31.

Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.

Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ, Levin VA.

Technol Cancer Res Treat. 2009 Apr;8(2):163-76.

32.

A new preclinical 3-dimensional agarose colony formation assay.

Kajiwara Y, Panchabhai S, Levin VA.

Technol Cancer Res Treat. 2008 Aug;7(4):329-34.

PMID:
18642971
33.

Long-term anti-inflammatory and antihistamine medication use and adult glioma risk.

Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1277-81. doi: 10.1158/1055-9965.EPI-07-2621.

34.

Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients.

Clarke JW, Chang EL, Levin VA, Mayr NA, Hong E, Cavaliere R, Lo SS.

Expert Rev Anticancer Ther. 2008 May;8(5):733-41. doi: 10.1586/14737140.8.5.733. Review. Erratum in: Expert Rev Anticancer Ther. 2011 Feb;11(2):323-4.

PMID:
18471046
35.

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK.

Neuro Oncol. 2008 Apr;10(2):216-22. doi: 10.1215/15228517-2007-060. Epub 2008 Feb 26.

36.

Chemotherapy as first line treatment for oligodendroglioma.

Kyritsis AP, Puduvalli VK, Levin VA.

J Neurooncol. 2008 Feb;86(3):361-2. Epub 2007 Aug 21. No abstract available.

PMID:
17710374
38.
39.

Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential.

Shantz LM, Levin VA.

Amino Acids. 2007 Aug;33(2):213-23. Epub 2007 Apr 19. Review.

PMID:
17443268
40.

Are gliomas preventable?

Levin VA.

Recent Results Cancer Res. 2007;174:205-15. Review.

PMID:
17302198
41.

Effect of bevacizumab on radiation necrosis of the brain.

Gonzalez J, Kumar AJ, Conrad CA, Levin VA.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6.

PMID:
17236958
42.

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA.

J Neurooncol. 2006 Oct;80(1):83-90. Epub 2006 Apr 25.

PMID:
16639492
43.

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M.

J Neurooncol. 2006 Jul;78(3):295-302. Epub 2006 Apr 25.

PMID:
16636750
44.

Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K.

J Neurooncol. 2006 May;78(1):85-90. Epub 2005 Nov 29.

PMID:
16391896
45.

Headache related to brain tumors.

Loghin M, Levin VA.

Curr Treat Options Neurol. 2006 Jan;8(1):21-32.

PMID:
16343358
46.

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.

Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M; North American Brain Tumor Consortium.

J Clin Oncol. 2004 Nov 1;22(21):4282-9.

47.

Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.

Levin VA, Jochec JL, Shantz LM, Koch PE, Pegg AE.

J Histochem Cytochem. 2004 Nov;52(11):1467-74.

48.

Polymorphisms of DNA repair genes and risk of glioma.

Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, Pudavalli V, Levin VA, Yung WK, Wei Q.

Cancer Res. 2004 Aug 15;64(16):5560-3.

49.

13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

See SJ, Levin VA, Yung WK, Hess KR, Groves MD.

Neuro Oncol. 2004 Jul;6(3):253-8.

50.

Basis and importance of Src as a target in cancer.

Levin VA.

Cancer Treat Res. 2004;119:89-119. Review. No abstract available.

PMID:
15164875

Supplemental Content

Loading ...
Support Center